News Foley Represents TCGX as Lead Investor in $127.5M Private Placement for Adverum Biotechnologies Foley & Larder LLP represented TCG Crossover (“TCGX”) as the lead investor in the $127.5…Louis LehotFebruary 13, 2024
News Foley Represents TCGX as Investor in $120M Private Placement for Silence Therapeutics Foley & Larder LLP represented TCG Crossover (“TCGX”) as an investor in the $120 million…Louis LehotFebruary 13, 2024
News Foley Represents TCGX as Lead Investor in $120M Private Financing for Mineralys Therapeutics Foley & Larder LLP recently represented TCG Crossover (“TCGX”) as a lead investor in the…Louis LehotFebruary 13, 2024
News Louis Lehot Quoted on Innovative Technology IPO Outlook Foley & Lardner LLP partner Louis Lehot is quoted in Law360, where he offers insight…Louis LehotFebruary 2, 2024
News Foley Represents TCGX as Investor in Tourmaline Bio, Concurrent with Merger with Talaris Therapeutics Foley & Lardner LLP represented TCGX as an investor in the $75 million private placement…Louis LehotJanuary 24, 2024
News Louis Lehot Offers Insight on Corporate M&A Momentum for 2024 Foley & Lardner LLP partner Louis Lehot is quoted in the Middle Market Growth article, “Corporate M&A…Louis LehotJanuary 24, 2024
News Foley Represents TCGX as Co-Lead Investor in $150M Series B Financing for Alkeus Pharmaceuticals Foley & Lardner LLP represented TCGX as co-lead investor in the $150 million Series B…Louis LehotJanuary 23, 2024
News Foley Represents NEA as Lead Investor in Comanche Biopharma Series B Round Foley & Lardner LLP recently represented New Enterprise Associates, Inc. (NEA) as lead investor in…Louis LehotJanuary 18, 2024
News Foley Represents TDK Ventures as Investor in Infinite Uptime Foley & Lardner LLP represented TDK Ventures as an investor in Infinite Uptime, the Industry…Louis LehotJanuary 17, 2024
News Foley Represents NEA as Investor in Series B Round for Fizz Foley & Lardner LLP represented New Enterprise Associates, Inc. (NEA) as co-lead investor in the…Louis LehotJanuary 16, 2024